Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S. O.
Right arrow Articles by Gao, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S. O.
Right arrow Articles by Gao, A. C.
Clinical Cancer Research Vol. 9, 370-376, January 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Interleukin-6 Promotes Androgen-independent Growth in LNCaP Human Prostate Cancer Cells1

Soo Ok Lee2, Wei Lou2, Min Hou2, Fernando de Miguel, Lizabeth Gerber and Allen C. Gao2,3

Department of Urology and Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213

Purpose: Prostate cancer frequently progresses from an initial androgen dependence to androgen independence, rendering the only effective androgen ablation therapy useless. The mechanism underlying the androgen-independent progression is incompletely understood. Interleukin (IL)-6 has been implicated in this androgen-independent progression. In this study, we tested whether IL-6 induces androgen-independent growth both in vitro and in vivo.

Experimental Design: IL-6 was expressed in androgen-sensitive LNCaP cells. The effects of IL-6 on androgen receptor activity was determined by Northern blots and gel shift assays. The effects of IL-6 on LNCaP cell growth were determined in vitro by MTT assay and in vivo.

Results: IL-6 can enhance the growth of androgen-sensitive LNCaP cells in the androgen-deprived condition in vitro, which is accompanied by elevation of androgen-regulated prostate-specific antigen mRNA expression. IL-6 promotes androgen-sensitive LNCaP cell tumor growth in the castrated male mice. IL-6 enhances androgen receptor DNA binding activity and nuclear translocation. The androgen-independent phenotype induced by IL-6 in LNCaP cells is accompanied by significant activation of signal transducers and activators of transcription 3 and mitogen-activated protein kinase signal pathways.

Conclusions: These studies clearly provide experimental evidence that IL-6 initiates and/or enhances the transition of prostate cancer cells from an androgen-dependent to an androgen-independent phenotype.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
J. Abdulghani, L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M. P. Lisanti, T. Zellweger, K. Alanen, T. Mirtti, et al.
Stat3 Promotes Metastatic Progression of Prostate Cancer
Am. J. Pathol., June 1, 2008; 172(6): 1717 - 1728.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Nadiminty, W. Lou, S. O. Lee, X. Lin, D. L. Trump, and A. C. Gao
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation
PNAS, May 9, 2006; 103(19): 7264 - 7269.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. J. Asirvatham, M. Schmidt, B. Gao, and J. Chaudhary
Androgens Regulate the Immune/Inflammatory Response and Cell Survival Pathways in Rat Ventral Prostate Epithelial Cells
Endocrinology, January 1, 2006; 147(1): 257 - 271.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Rocchi, E. Beraldi, S. Ettinger, L. Fazli, R. L. Vessella, C. Nelson, and M. Gleave
Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3-Mediated Suppression of Apoptosis
Cancer Res., December 1, 2005; 65(23): 11083 - 11093.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall
p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6
Cancer Res., July 1, 2005; 65(13): 5965 - 5973.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Gao, P. Lee, H. Wang, W. Gerald, M. Adler, L. Zhang, Y.-F. Wang, and Z. Wang
The Androgen Receptor Directly Targets the Cellular Fas/FasL-Associated Death Domain Protein-Like Inhibitory Protein Gene to Promote the Androgen-Independent Growth of Prostate Cancer Cells
Mol. Endocrinol., July 1, 2005; 19(7): 1792 - 1802.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. O. Lee, N. Nadiminty, X. X. Wu, W. Lou, Y. Dong, C. Ip, S. A. Onate, and A. C. Gao
Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells
Cancer Res., April 15, 2005; 65(8): 3487 - 3492.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. J. George, S. Halabi, T. F. Shepard, B. Sanford, N. J. Vogelzang, E. J. Small, and P. W. Kantoff
The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480
Clin. Cancer Res., March 1, 2005; 11(5): 1815 - 1820.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Sun, M. Hedelin, S. L. Zheng, H.-O. Adami, J. Bensen, K. Augustsson-Balter, B. Chang, J. Adolfsson, T. Adams, A. Turner, et al.
Interleukin-6 Sequence Variants Are not Associated with Prostate Cancer Risk
Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1677 - 1679.
[Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Blaszczyk, B. A. Masri, N. R. Mawji, T. Ueda, G. McAlinden, C. P. Duncan, N. Bruchovsky, H.-U. Schweikert, D. Schnabel, E. C. Jones, et al.
Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells
Clin. Cancer Res., March 1, 2004; 10(5): 1860 - 1869.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. H. Ngo, R. J. Barnard, T. Anton, C. Tran, D. Elashoff, D. Heber, S. J. Freedland, and W. J. Aronson
Effect of Isocaloric Low-Fat Diet on Prostate Cancer Xenograft Progression to Androgen Independence
Cancer Res., February 15, 2004; 64(4): 1252 - 1254.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.